RIP1 Kinase Inhibitor Compounds for Targeted Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases and conditions associated with RIP1 kinase, such as inflammatory bowel disease and psoriasis, are inadequate in effectively targeting this kinase to manage inflammation and necroptotic cell death.
Innovation Solution
Development of compounds with specific structural formulas, including various heteroaryl and spiroheterocyclyl groups, that inhibit RIP1 kinase activity, which can be administered alone or in pharmaceutical compositions to treat diseases like Parkinson's, Alzheimer's, and multiple sclerosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for inflammatory diseases, then they can be administered to patients, but they fail to effectively target RIP1 kinase to manage inflammation and necroptotic cell death
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific molecular structures (Formula I) that have optimized parameters for RIP1 kinase binding. The compounds feature specific heteroaryl groups, substituent patterns, and structural configurations that enhance their ability to selectively inhibit RIP1 kinase, thereby improving treatment effectiveness and targeting capability simultaneously
2Reliability
If compounds with specific structural formulas are developed to inhibit RIP1 kinase, then therapeutic benefits are achieved, but the complexity of the compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the complex RIP1 kinase inhibitor into distinct structural modules represented by Formula I, where different components (heteroaryl group, substituent R1-R6, core structure) can be independently optimized. This modular approach allows systematic development of compounds with varying degrees of complexity while maintaining therapeutic efficacy
Solution Approach 2:
The patent uses parameter changes to optimize compound structure by defining specific structural parameters in Formula I (such as heteroaryl ring types, substituent positions, and molecular weight ranges) that balance therapeutic efficacy with structural complexity, enabling rational drug design
Data Source
AI summary
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.